These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 26126066)

  • 1. The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy.
    Mangia A; Caldarola L; Dell'Endice S; Scarpi E; Saragoni L; Monti M; Santini D; Brunetti O; Simone G; Silvestris N
    Cancer Biol Ther; 2015; 16(8):1140-7. PubMed ID: 26126066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NHERF1 and tumor microenvironment: a new scene in invasive breast carcinoma.
    Saponaro C; Vagheggini A; Scarpi E; Centonze M; Catacchio I; Popescu O; Pastena MI; Giotta F; Silvestris N; Mangia A
    J Exp Clin Cancer Res; 2018 May; 37(1):96. PubMed ID: 29716631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX).
    Wang Y; Zhuang RY; Yu YY; Yu S; Hou J; Ji Y; Sun YH; Shen KT; Shen ZB; Liu FL; Zhao NQ; Liu TS
    Oncotarget; 2016 Nov; 7(46):76298-76307. PubMed ID: 27602586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Correlation of chemosensitivity tested using histoculture drug response assay to expression of multidrug resistance genes and proteins in colorectal cancer tissues].
    Yuan SQ; Zhou ZW; Liang YJ; Fu LW; Chen G; Qiu HB; Zhang LY
    Ai Zheng; 2009 Sep; 28(9):932-8. PubMed ID: 19728910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity of gastric cancer cells to chemotherapy drugs in elderly patients and its correlation with cyclooxygenase-2 expression.
    Qiu ZQ; Qiu ZR
    Asian Pac J Cancer Prev; 2015; 16(8):3447-50. PubMed ID: 25921160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial.
    Ochenduszko S; Puskulluoglu M; Konopka K; Fijorek K; Urbanczyk K; Budzynski A; Matlok M; Lazar A; Sinczak-Kuta A; Pedziwiatr M; Krzemieniecki K
    Med Oncol; 2015 Oct; 32(10):242. PubMed ID: 26354521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear NHERF1 expression as a prognostic marker in breast cancer.
    Paradiso A; Scarpi E; Malfettone A; Addati T; Giotta F; Simone G; Amadori D; Mangia A
    Cell Death Dis; 2013 Nov; 4(11):e904. PubMed ID: 24201803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Supplementary Omegaven® on the Clinical Outcome of Patients With Advanced Esophagogastric Adenocarcinoma Receiving Palliative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy: A Phase II clinical trial.
    Eltweri AM; Thomas AL; Chung WY; Morgan B; Thompson J; Dennison AR; Bowrey DJ
    Anticancer Res; 2019 Feb; 39(2):853-861. PubMed ID: 30711967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epirubicin, oxaliplatin, and capectabine is just as "MAGIC"al as epirubicin, cisplatin, and fluorouracil perioperative chemotherapy for resectable locally advanced gastro-oesophageal cancer.
    Sirohi B; Barreto SG; Singh A; Batra S; Mittra A; Rastogia S; Ramadwar M; Shetty N; Goel M; Shrikhande SV
    J Cancer Res Ther; 2014; 10(4):866-70. PubMed ID: 25579520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relationship between the expression of hypoxia-inducible factor-1alpha and chemotherapy response in gastric carcinoma].
    Wu Q; Li ZS; Li DW; Peng ZH; Yang ZR
    Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Sep; 12(5):498-501. PubMed ID: 19742344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of nuclear NHERF1 in advanced colorectal cancer: association with hypoxic microenvironment and tumor invasive phenotype.
    Malfettone A; Silvestris N; Paradiso A; Mattioli E; Simone G; Mangia A
    Exp Mol Pathol; 2012 Jun; 92(3):296-303. PubMed ID: 22440733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
    Wan Y; Hui H; Wang X; Wu J; Sun S
    Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):28-34. PubMed ID: 26796803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial.
    Rosati G; Cella CA; Cavanna L; Codecà C; Prisciandaro M; Mosconi S; Luchena G; Silvestris N; Bernardini I; Casaretti R; Zoratto F; Amoroso D; Ciarlo A; Barni S; Cascinu S; Davite C; Di Sanzo A; Casolaro A; Bilancia D; Labianca R
    Gastric Cancer; 2022 Jul; 25(4):783-793. PubMed ID: 35352176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIF-1α inhibition reverses multidrug resistance in colon cancer cells via downregulation of MDR1/P-glycoprotein.
    Chen J; Ding Z; Peng Y; Pan F; Li J; Zou L; Zhang Y; Liang H
    PLoS One; 2014; 9(6):e98882. PubMed ID: 24901645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.
    Gong J; Liu T; Fan Q; Bai L; Bi F; Qin S; Wang J; Xu N; Cheng Y; Bai Y; Liu W; Wang L; Shen L
    BMC Cancer; 2016 Feb; 16():68. PubMed ID: 26857702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of hypoxia-inducible factor 1α in gastric cancer and its clinical signficance].
    Wu YL; Hu LN; Zheng CD; Sun RC; Zhang SX; Yan Q; Li YX
    Zhonghua Yi Xue Za Zhi; 2016 May; 96(18):1418-23. PubMed ID: 27266349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NHERF1/EBP50 and NF2 as diagnostic markers for choroid plexus tumors.
    Georgescu MM; Mobley BC; Orr BA; Shang P; Lehman NL; Zhu X; O'Neill TJ; Rajaram V; Hatanpaa KJ; Timmons CF; Raisanen JM
    Acta Neuropathol Commun; 2016 May; 4(1):55. PubMed ID: 27229317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients.
    Mangia A; Scarpi E; Partipilo G; Schirosi L; Opinto G; Giotta F; Simone G
    Oncotarget; 2017 Sep; 8(39):65730-65742. PubMed ID: 29029467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study.
    Meulendijks D; de Groot JW; Los M; Boers JE; Beerepoot LV; Polee MB; Beeker A; Portielje JE; Goey SH; de Jong RS; Vanhoutvin SA; Kuiper M; Sikorska K; Pluim D; Beijnen JH; Schellens JH; Grootscholten C; Tesselaar ME; Cats A
    Cancer; 2016 May; 122(9):1434-43. PubMed ID: 26970343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma.
    Pluschnig U; Schoppmann SF; Preusser M; Datler P; Asari R; Ba-Ssalamah A; Schwameis K; Birner P; Zacherl J; Hejna M
    Anticancer Res; 2013 Mar; 33(3):1035-9. PubMed ID: 23482778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.